Study Design and Inclusion Criteria of the EV-103 Study in Advanced Urothelial Carcinoma

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the Society of Urologic Oncology.

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.

Treatment of unresponsive non–muscle-invasive bladder cancer with nadofaragene firadenovec showed a 66% chance of survival and cystectomy-free status at 60 months.

Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies is relevant.

In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.

Avelumab plus best supportive care improved survival vs best supportive care alone in advanced urothelial carcinoma, regardless of diabetes status.